Cara Therapeutics, Inc. (CARA)

Market Cap	41.04M
Revenue (ttm)	16.94M
Net Income (ttm)	-122.54M
Shares Out	54.68M
EPS (ttm)	-2.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	224,216
Open	0.800
Previous Close	0.805
Day's Range	0.750 - 0.800
52-Week Range	0.500 - 4.450
Beta	0.73
Analysts	Strong Buy
Price Target	10.93 (+1,357.14%)
Earnings Date	May 13, 2024

About CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruish...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 31, 2014
• Employees: 55
• Stock Exchange: NASDAQ
• Ticker Symbol: CARA

Financial Performance

In 2023, CARA's revenue was $20.97 million, a decrease of -49.92% compared to the previous year's $41.87 million. Losses were -$118.51 million, 38.7% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for CARA stock is "Strong Buy." The 12-month stock price forecast is $10.93, which is an increase of 1,357.14% from the latest price.

Price Target

$10.93

(1,357.14% upside)

Analyst Consensus: Strong Buy